Overview

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2023-01-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.

Phase:

Phase 3

Details

Lead Sponsor:

Isofol Medical AB

Treatments:

Bevacizumab
Fluorouracil
Leucovorin
Oxaliplatin